168 related articles for article (PubMed ID: 17521912)
1. The biology and chemistry of hyperlipidemia.
Jain KS; Kathiravan MK; Somani RS; Shishoo CJ
Bioorg Med Chem; 2007 Jul; 15(14):4674-99. PubMed ID: 17521912
[TBL] [Abstract][Full Text] [Related]
2. [Hyperlipidemia and atherosclerosis: epidemiology, biochemistry and therapy].
Ducobu J; Berghmans L; Carpentier YA; Daubresse JC; Kornitzer M; Balasse E
Rev Med Brux; 1993 Oct; 14(8):239-45. PubMed ID: 8272680
[TBL] [Abstract][Full Text] [Related]
3. [Current approaches to the diagnosis and correction of atherogenic disorders in flight personnel].
Orlova TA; Khudov VV; Bobrovnitskiĭ IP
Aviakosm Ekolog Med; 1999; 33(6):3-11. PubMed ID: 10656128
[TBL] [Abstract][Full Text] [Related]
4. Lipid-lowering effects of polydatin from Polygonum cuspidatum in hyperlipidemic hamsters.
Du J; Sun LN; Xing WW; Huang BK; Jia M; Wu JZ; Zhang H; Qin LP
Phytomedicine; 2009 Jun; 16(6-7):652-8. PubMed ID: 19106037
[TBL] [Abstract][Full Text] [Related]
5. Current drug targets for antihyperlipidemic therapy.
Jain KS; Kulkarni RR; Jain DP
Mini Rev Med Chem; 2010 Mar; 10(3):232-62. PubMed ID: 20105132
[TBL] [Abstract][Full Text] [Related]
6. Current world literature.
Curr Opin Lipidol; 2011 Aug; 22(4):308-10. PubMed ID: 21743305
[No Abstract] [Full Text] [Related]
7. Optimal risk factor modification and medical management of the patient with peripheral arterial disease.
Chi YW; Jaff MR
Catheter Cardiovasc Interv; 2008 Mar; 71(4):475-89. PubMed ID: 18307227
[TBL] [Abstract][Full Text] [Related]
8. Risk factor control in patients with Type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR).
Gudbjörnsdottir S; Eeg-Olofsson K; Cederholm J; Zethelius B; Eliasson B; Nilsson PM;
Diabet Med; 2009 Jan; 26(1):53-60. PubMed ID: 19125761
[TBL] [Abstract][Full Text] [Related]
9. Urotensin II receptor knockout mice on an ApoE knockout background fed a high-fat diet exhibit an enhanced hyperlipidemic and atherosclerotic phenotype.
Bousette N; D'Orleans-Juste P; Kiss RS; You Z; Genest J; Al-Ramli W; Qureshi ST; Gramolini A; Behm D; Ohlstein EH; Harrison SM; Douglas SA; Giaid A
Circ Res; 2009 Sep; 105(7):686-95, 19 p following 695. PubMed ID: 19696412
[TBL] [Abstract][Full Text] [Related]
10. Translating molecular discoveries into new therapies for atherosclerosis.
Rader DJ; Daugherty A
Nature; 2008 Feb; 451(7181):904-13. PubMed ID: 18288179
[TBL] [Abstract][Full Text] [Related]
11. Atherogenic lipoprotein subprofiling.
Ellington AA; Kullo IJ
Adv Clin Chem; 2008; 46():295-317. PubMed ID: 19004193
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hyperlipidemia.
Kane JP; Malloy MJ
Annu Rev Med; 1990; 41():471-82. PubMed ID: 2184745
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelium in atherosclerosis.
Sima AV; Stancu CS; Simionescu M
Cell Tissue Res; 2009 Jan; 335(1):191-203. PubMed ID: 18797930
[TBL] [Abstract][Full Text] [Related]
14. Advances in the management of hyperlipidemia-induced atherosclerosis.
Tannock LR
Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):369-83. PubMed ID: 18327996
[TBL] [Abstract][Full Text] [Related]
15. [C-reactive protein and homocysteine as risk factors of atherosclerosis].
Jarosz A; Nowicka G
Przegl Lek; 2008; 65(6):268-72. PubMed ID: 18853656
[TBL] [Abstract][Full Text] [Related]
16. Macrophage beta3 integrin suppresses hyperlipidemia-induced inflammation by modulating TNFalpha expression.
Schneider JG; Zhu Y; Coleman T; Semenkovich CF
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2699-706. PubMed ID: 17951320
[TBL] [Abstract][Full Text] [Related]
17. Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents.
Dupuy AM; Carrière I; Scali J; Cristol JP; Ritchie K; Dartigues JF; Gambert P; Ancelin ML
Climacteric; 2008 Feb; 11(1):74-83. PubMed ID: 18202967
[TBL] [Abstract][Full Text] [Related]
18. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.
Ferdinandy P; Schulz R; Baxter GF
Pharmacol Rev; 2007 Dec; 59(4):418-58. PubMed ID: 18048761
[TBL] [Abstract][Full Text] [Related]
19. New pharmacological agents under clinical investigation for treating disorders of lipoprotein regulation leading to atherosclerosis.
Gallup E; Dujovne C
Expert Opin Investig Drugs; 2001 Mar; 10(3):561-7. PubMed ID: 11227051
[TBL] [Abstract][Full Text] [Related]
20. New insights into lipid metabolism in chronic kidney disease: what are the practical implications?
Kaysen GA
Blood Purif; 2009; 27(1):86-91. PubMed ID: 19169024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
